SCHEDULE: Phibro Health Insider Adopts 10b5-1 Sales Plan

BFI Co., LLC, controlled by Jack C. Bendheim, has adopted a Rule 10b5-1 sales plan to sell up to 528,000 shares of Phibro Animal Health Class A Common Stock for diversification.

Summary

• BFI Co., LLC and Jack C. Bendheim, collectively the Reporting Persons, filed Amendment No. 23 to their Schedule 13D for Phibro Animal Health Corporation.
• As of December 15, 2025, the Reporting Persons beneficially own 20,000,234 shares of Common Stock, representing 49.3% of the total Class A Common Stock outstanding (assuming conversion of Class B shares).
• On December 11, 2025, BFI Co., LLC entered into a Rule 10b5-1 sales plan to sell up to 528,000 shares of Class A Common Stock through September 15, 2026.
• The sales plan is designed to allow BFI to diversify its investment portfolio over an extended period, subject to minimum sale prices and daily volume limits.
• The first possible trade date under the Sales Plan is March 13, 2026.
• If all shares under the plan are sold, BFI will still hold 19,472,234 shares (39,200 Class A and 19,433,034 Class B convertible to Class A).
• Within the 60 days prior to December 15, 2025, the Reporting Persons disposed of 180,000 shares of Class A Common Stock in market transactions, with weighted average prices ranging from $40.0319 to $45.8149.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the use of a Rule 10b5-1 plan for diversification is a common and structured approach. The insider retains a very significant stake, suggesting continued confidence, but the sale itself is not a positive signal for immediate stock performance.

Positives

• The adoption of a Rule 10b5-1 plan allows for an orderly and pre-scheduled diversification of a significant shareholder's investment, potentially reducing market impact compared to unscheduled large block sales.
• Even after the planned sales, the Reporting Persons will retain a substantial ownership stake of over 19 million shares, indicating continued long-term interest in the company.

Negatives

• A significant shareholder's decision to sell a portion of their holdings, even for diversification, could be perceived negatively by the market, potentially signaling a lack of conviction or a desire to reduce exposure.
• The sale of up to 528,000 shares represents a notable volume that could exert downward pressure on the stock price, especially if market conditions are unfavorable.

Risks

• The sale of a large block of shares by a significant insider could be interpreted by the market as a negative signal, potentially leading to a decrease in investor confidence and share price.
• The actual sale prices under the Rule 10b5-1 plan are subject to market conditions and minimum price thresholds, meaning the full 528,000 shares may not be sold or may be sold at varying prices.

Future Outlook

The Reporting Persons may consider and formulate plans regarding investment alternatives and may engage in discussions or proposals with management or the Board of Directors of Phibro Animal Health Corporation in the future, as permitted by law.

Industry Context

This filing primarily concerns a change in beneficial ownership and a planned stock sale by a significant insider, rather than operational or strategic updates. Therefore, it does not directly relate to broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Potential for increased selling pressure on Class A Common Stock due to the Rule 10b5-1 plan. May raise questions about insider confidence, though the stated purpose is diversification.
• Company (Phibro Animal Health Corporation): No direct operational impact, but the market's reaction to insider selling could affect stock valuation.

Next Steps

• Execution of sales under the Rule 10b5-1 plan, commencing March 13, 2026, and continuing through September 15, 2026, or until all shares are sold.
• Ongoing evaluation of investment alternatives by the Reporting Persons.
• Potential future discussions or proposals by Reporting Persons with Phibro Animal Health Corporation management or Board of Directors.

Key Dates

Recommendation

The filing indicates a significant insider, Jack C. Bendheim through BFI Co., LLC, is initiating a Rule 10b5-1 plan to sell a portion of their holdings for diversification. While insider selling can be a negative signal, the structured nature of the 10b5-1 plan and the fact that a substantial stake (over 19 million shares) will still be retained suggests this is a portfolio management decision rather than a complete loss of confidence. The immediate impact might be some selling pressure, but the long-term fundamentals of the company are not directly addressed by this filing. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor the sales and company performance without making immediate drastic changes based solely on this insider selling.

Keywords

Phibro Animal Health, PAHC, Schedule 13D, Insider Selling, Rule 10b5-1 Plan, Stock Diversification, Jack C. Bendheim, BFI Co. LLC, Class A Common Stock, Class B Common Stock, Shareholder Update